India's Sun Pharma to buy Ranbaxy in $3.2 billion deal

[admin]

TOKYO (Reuters) - India's Sun Pharmaceutical Industries Ltd said it will buy generic drug maker Ranbaxy Laboratories Ltd , which has hit regulatory snags in its key U.S. market over quality issues, in an all-share deal with total equity value of $3.2 billion.









More...